IP Library Granted Patent US 12,544,330
Granted Patent B2
US 12,544,330 · App. 18/000,117 · Granted Feb 10, 2026

Long-lasting reabsorbable subcutaneous implant with sustained release of pre-concentrated pharmacologically active substance in polymer for the treatment of chronic adrenal insufficiency or hypocortisolism

Inventor: Edson Luiz Peracchi (Curitiba, BR)
A61K9/0024A61K31/573A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,544,330
App. No.
18/000,117
Granted
Feb 10, 2026
Kind
B2
Abstract

Long-acting resorbable subcutaneous implant with extended release of pre-concentrated pharmacologically active substance in polymer for treatment of chronic adrenal insufficiency. The implant is inserted subcutaneously and has continuous release of the active ingredient for an extended period of time. The implant may have in its constitution only hydrocortisone but is preferably formed by hydrocortisone particles homogeneously dispersed in a bio erodible and bioabsorbable polymer matrix. Such a polymer matrix may be formed of a polymer or a polymer blend. The release of the drug in this system occurs through diffusion, at a relatively constant rate, and it is possible to change the rate of release of the drug through the thickness or material of this membrane.

Claims (12)

1 . A long-lasting reabsorbable subcutaneous implant with sustained release of pre-concentrated pharmacologically active substance for the treatment of chronic adrenal insufficiency or hypercortisolism comprising:

a bioabsorbable polymer matrix;

between 5 mg to 250 mg of hydrocortisone dispersed homogeneously in said bioabsorbable polymer matrix, said bioabsorbable polymer matrix having a weight that is between 1 percent and 20 percent that of said hydrocortisone.

2 . The long-lasting reabsorbable subcutaneous implant according to claim 1 , wherein said bioabsorbable polymer matrix is formed from a material selected from a group consisting of poly(D-lactic acid), poly(L-lactic acid), poly(racemic lactic acid), poly(glycolic acid), natural gum, synthetic gum and wax.

3 . The long-lasting reabsorbable subcutaneous implant according to claim 1 , wherein said hydrocortisone is mixed with said bioabsorbable polymer matrix to form a homogeneous mixture, wherein said homogenous mixture is dried and molded into said subcutaneous implant.

4 . The long-lasting reabsorbable subcutaneous implant according to claim 3 , wherein said homogenous mixture is formed by compression molding to form said subcutaneous implant, wherein said subcutaneous implant is sterilized by heat, in an oven at 90° C., for 1 hour.

5 . The long-lasting reabsorbable subcutaneous implant according to claim 1 , wherein at least part of said subcutaneous implant has a bioabsorbable coating, wherein said bioabsorbable coating has a thickness between 0.1 mm and 0.7 mm, said bioabsorbable coating containing poly(lactic-co-glycolic acid) and copolymers of D, L-lactic acid.

6 . A long-lasting reabsorbable subcutaneous implant with sustained release of pre-concentrated pharmacologically active substance for the treatment of chronic adrenal insufficiency or hypercortisolism, comprising:

5 mg to 250 mg of hydrocortisone;

a central core of a polymer matrix, wherein said hydrocortisone is intermixed with said polymer matrix and said polymer matrix has a weight that is between 1 percent and 20 percent that of said hydrocortisone;

a non-degradable polymeric membrane coating at least part of said central core.

7 . The long-lasting reabsorbable subcutaneous implant, according to claim 6 , wherein said non-degradable polymeric membrane is selected from a group consisting of silicone, urethane, acrylates and their copolymers, copolymers of polyvinylidene fluoride, ethylene polyethylene vinyl acetate-vinyl and dimethylpolysiloxane, wherein said non-degradable polymeric membrane has a thickness between 0.2 mm and 1 mm.

Priority Claims (1)
BR 1020200109235 · May 29, 2020 · national
Continuity (1)
Related Publication 20230190641A1 · Jun 22, 2023
References Cited (9)
US 4957119A · deNijs · 1990 [cited by applicant]
US 9980850B2 · Baillie et al. · 2018 [cited by applicant]
US 20070031472A1 · Huang · 2007 [cited by applicant]
US 20190298646A1 · Allred · 2019 [cited by applicant]
BR 1020160182069 · 2018 [cited by applicant]
WO WO2007089544 · 2007 [cited by applicant]
WO WO2008157057 · 2008 [cited by examiner]
WO WO2011139595 · 2011 [cited by examiner]
WO 102016018206 · 2016 [cited by examiner]